Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FIRST-QUARTER 2024 RESULTS • First-quarter sales from continuing operations of $3.59 billion increased 2% on a reported basis and 3% on a constant currency basis, exceeding the company’s previously issued guidance1 • First-quarter U.S. GAAP2 diluted earnings per share (EPS) from continuing operations were $0.07 and adjusted diluted EPS from continuing operations were $0.65, exceeding the company’s previously issued guidance • Baxter now expects full-year 202 ...

Analysts on Wall Street project that Baxter International (BAX) will announce quarterly earnings of $0.61 per share in its forthcoming report, representing an increase of 3.4% year over year. Revenues are projected to reach $3.55 billion, declining 2.7% from the same quarter last year. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe. Prior to ...

Baxter International, Inc.新产品发布 - Baxter International, Inc.最近在美国推出了五种注射产品，扩大了其制药产品组合[1] - 这些新产品提供了现成的配方，满足了关键治疗领域患者的需求，并为医疗专业人员提供了额外的便利[2] Baxter International, Inc.股价表现 - Baxter的股价在过去六个月中上涨了32.3%，表现优于行业的21.7%和标普500指数的19.1%[3]

The Zacks Medical sector is facing headwinds in the form of inflation, higher interest rates, supply-chain disruptions and high operating costs. These factors are likely to put pressure on the industry players’ margin. Amid these ongoing headwinds, the sector has gained 2.5% until Apr 9, underperforming the S&P 500 Index’s 9.4% gain. Meanwhile, amid the rising risk of a downtrend in the market, it would be a wise decision to invest in some dividend-paying companies like Cardinal Health (CAH) , Baxter Intern ...

Baxter International (BAX) is poised for growth, given the demand for its medically essential products, coupled with transformational actions. However, inflationary pressure remains a concern. Shares of this Zacks Rank #3 (Hold) company have gained 10.8% year to date compared with the industry's 5.3% growth. The S&P 500 Index has increased 9.4% in the same time frame. BAX, with a market capitalization of $21.46 billion, is a global medical technology company providing items such as kidney-dialysis equipment ...

Baxter International Inc. - Baxter最近获得FDA的510(k)清关，为其Novum IQ大容量输液泵（LVP）配备了Dose IQ安全软件[1] - 公司计划通过持续产品开发和额外的监管提交来扩展平台[2] - 最新的监管清关预计将显著提升Baxter的医疗产品和疗法业务，并巩固其在输液疗法领域的立足点[3]

Baxter International Inc. (NYSE:BAX)股票走势 - Baxter International Inc. (NYSE:BAX)是一家医疗设备公司[1] - BAX股价在2022年2月达到每股85美元，但在2022年初开始下跌[4] - BAX在2023年10月触底后，股价开始反弹并表现出上升趋势[4] BAX股票分析 - BAX的短期和长期动量都显示出看涨的迹象[5] - 机构投资者正在积极买入BAX股票，显示出股价被低估的迹象[6] - BAX相对于标普500指数的表现一直在波动，但最近有所改善[7] 投资建议 - 在购买BAX股票时，应制定风险管理计划，以避免大额损失[8] - 总体而言，BAX目前看起来是一个买入的机会，但仍需谨慎管理风险[9]

公司动态 - Spectral Medical Inc.宣布达到TIGRIS试验的中期招募目标，招募了第90位患者[1] - 公司与Baxter International签订了独家分销协议，根据协议，Baxter有权在中期招募时向Spectral支付第二个里程碑款项，以保持其PMX独家分销权[2] - Spectral是一家正在寻求美国FDA批准其用于治疗感染性休克患者的独特产品Toraymyxin™（PMX）的第三阶段公司，该产品已在日本和欧洲获得批准，并在北美每年约有33万名感染性休克患者[3]

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on April 1, 2024, to stockholders of record as of March 1, 2024. The indicated annual dividend rate is $1.16 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, crit ...

Baxter International Inc. (BAX) reported fourth-quarter 2023 adjusted earnings per share (EPS) from continuing operations of 88 cents, which beat the Zacks Consensus Estimate of 86 cents by 2.3%. The bottom line improved 13% from the year-ago quarter’s level. On a GAAP basis, the EPS from continuing operations was 14 cents, down 50% from the prior-year quarter’s level. The company recorded $2.79 billion as goodwill impairment in the prior-year quarter. Continuing operations exclude Baxter's BioPharma Soluti ...